InsiderTrades.com logo
Francesca Barone net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Francesca Barone Biography and Net Worth

Chief Scientific Officer of Candel Therapeutics

Dr. Francesca Barone serves as Chief Scientific Officer at Candel Therapeutics. She oversees scientific discovery, the development of our novel viral immunotherapies and our biomarker strategy across our broad clinical portfolio. Dr. Barone previously served as Vice President and Head of Experimental Medicine at Flagship Pioneering’s Kintai Therapeutics, now Senda Biosciences. She has previously designed experimental medicine clinical trials to support rigorous decision-making across various programs and indications.

Before joining the industry, Dr. Barone held the academic position of Reader in Translational Rheumatology and Academic Director of Business Engagement for the College of Medical and Dental Sciences at the University of Birmingham. While there, she was also the Director of the laboratories for Immuno-phenotyping in the Institute of Translational Medicine. Dr. Barone earned her M.D. and completed a specialization in Rheumatology from the University of Rome, Sapienza, with merit and her Ph.D. from King’s College London.

What is Francesca Barone's net worth?

The estimated net worth of Francesca Barone is at least $582.14 thousand as of January 15th, 2025. Dr. Barone owns 110,673 shares of Candel Therapeutics stock worth more than $582,140 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Barone may own. Additionally, Dr. Barone receives an annual salary of $506,760.00 as Chief Scientific Officer at Candel Therapeutics. Learn More about Francesca Barone's net worth.

How old is Francesca Barone?

Dr. Barone is currently 46 years old. There are 6 older executives and no younger executives at Candel Therapeutics. The oldest executive at Candel Therapeutics is Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D., Founder & Director, who is 65 years old. Learn More on Francesca Barone's age.

What is Francesca Barone's salary?

As the Chief Scientific Officer of Candel Therapeutics, Inc., Dr. Barone earns $506,760.00 per year. The highest earning executive at Candel Therapeutics is Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D., President, CEO & Director, who commands a salary of $1,120,000.00 per year. Learn More on Francesca Barone's salary.

How do I contact Francesca Barone?

The corporate mailing address for Dr. Barone and other Candel Therapeutics executives is , , . Candel Therapeutics can also be reached via phone at 617-916-5445 and via email at [email protected]. Learn More on Francesca Barone's contact information.

Has Francesca Barone been buying or selling shares of Candel Therapeutics?

Francesca Barone has not been actively trading shares of Candel Therapeutics in the last ninety days. Most recently, Francesca Barone sold 13,534 shares of the business's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a transaction totalling $97,715.48. Following the completion of the sale, the insider now directly owns 110,673 shares of the company's stock, valued at $799,059.06. Learn More on Francesca Barone's trading history.

Who are Candel Therapeutics' active insiders?

Candel Therapeutics' insider roster includes Francesca Barone (Chief Scientific Officer), Paul Manning (Director), William Nichols (Chief Medical Officer), Charles Schoch (CFO), and Seshu Tyagarajan (CTO). Learn More on Candel Therapeutics' active insiders.

Are insiders buying or selling shares of Candel Therapeutics?

During the last twelve months, Candel Therapeutics insiders bought shares 1 times. They purchased a total of 1,250,000 shares worth more than $7,500,000.00. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 79,525 shares worth more than $644,010.84. The most recent insider tranaction occured on July, 28th when insider William Garrett Nichols sold 937 shares worth more than $6,540.26. Insiders at Candel Therapeutics own 16.6% of the company. Learn More about insider trades at Candel Therapeutics.

Information on this page was last updated on 7/28/2025.

Francesca Barone Insider Trading History at Candel Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/15/2025Sell13,534$7.22$97,715.48110,673View SEC Filing Icon  
1/8/2025Sell13,673$8.22$112,392.06124,207View SEC Filing Icon  
12/8/2022Buy1,238$1.61$1,993.182,738View SEC Filing Icon  
See Full Table

Francesca Barone Buying and Selling Activity at Candel Therapeutics

This chart shows Francesca Barone's buying and selling at Candel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Candel Therapeutics Company Overview

Candel Therapeutics logo
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Read More

Today's Range

Now: $5.26
Low: $4.97
High: $5.32

50 Day Range

MA: $5.21
Low: $4.42
High: $6.55

2 Week Range

Now: $5.26
Low: $4.25
High: $14.60

Volume

1,381,428 shs

Average Volume

682,855 shs

Market Capitalization

$288.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A